RTW Investments’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

RTW Investments’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,272,104	Closed	-$351M	–	70
2023 Q1	$351M	Sell	3,272,104 -82,199	-2%	-$9.46M	7.31%	1
2022 Q4	$369M	Buy	3,354,303 +164,698	+5%	+$10.7M	7.53%	2
2022 Q3	$188M	Hold	3,189,605	–	–	4.34%	7
2022 Q2	$90M	Buy	3,189,605 +431,658	+16%	+$12.5M	2.33%	12
2022 Q1	$104M	Sell	2,757,947 -506,084	-16%	-$20M	2.16%	19
2021 Q4	$129M	Hold	3,264,031	–	–	1.88%	15
2021 Q3	$77.4M	Hold	3,264,031	–	–	1.17%	28
2021 Q2	$76M	Hold	3,264,031	–	–	1.15%	26
2021 Q1	$51.7M	Buy	+3,264,031	New	+$67.4M	0.81%	38

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

RTW Investments's RXDX Position: Q2 2023 in Review

RTW Investments sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 3,272,104 shares — an estimated $351M sold.

RTW Investments first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $369M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

RTW Investments reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
RTW Investments sold 3,272,104 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $351M.
RTW Investments first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
RTW Investments's Prometheus Biosciences, Inc. Common Stock position peaked at $369M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on RTW Investments's 13F filing for Q2 2023, filed 14 Aug 2023.